Trials / Completed
CompletedNCT02916095
Kanitinib in Treating Patients With Advanced Solid Tumors
Evaluation Kanitinib Treatment of Recurrent or Metastatic Malignant Solid Tumors Safety, Tolerability and Pharmacokinetic Open, Dose Escalation Phase I Clinical Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.
Detailed description
Evaluation of recurrent or metastatic solid tumor patients on Kanitinib single dose and continuous multiple dose safety and tolerability, and to determine the maximum tolerated Connie imatinib dose (MTD) or the phase II trial recommended dosage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kanitinib | Oral administration of Kanitinib tablets. |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2020-01-01
- Completion
- 2020-07-01
- First posted
- 2016-09-27
- Last updated
- 2020-09-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02916095. Inclusion in this directory is not an endorsement.